Lung cancer drugs erlotinib and gefitinib under review by NICE
The National Institute for Health and Care Excellence is reviewing its guidance on the use of two lung cancer drugs – erlotinib and gefitinib – in response to changing clinical practice.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
Customised email alerts straight to your inbox (over 30 alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units